CARSGEN-B (02171) rose more than 3%, with the stock up 3.13% to HK$21.76 at the time of writing. The trading volume was HK$7.9942 million.

Recently, CARSGEN-B announced that abstracts summarizing the results of Investigator-Initiated Trials for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia, and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma, have been accepted for poster presentation at the 2026 European Hematology Association Annual Congress. The abstracts and further details will be released after 15:30 Central European Summer Time on May 12, 2026.

CT0596 is a universal CAR-T cell therapy targeting BCMA, developed on CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell leukemia in 2026. CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. The company plans to commence a Phase Ib registration clinical trial for this product in R/R B-NHL in 2026.